The Kinase Inhibitor GNF-7 Is Synthetically Lethal in Topoisomerase 1-Deficient Ewing Sarcoma
Together, these results suggest that GNF-7 or small molecules with a similar kinase profile could be effective treatments for ES patients in combination with TOP1 inhibitors or for those patients who have developed resistance to TOP1 inhibitors.
Authors
- Jack F. Shern (ORCID: https://orcid.org/0000-0001-5579-7625)
- Kelli M. Wilson (ORCID: https://orcid.org/0000-0003-2636-2766)
- Craig J. Thomas (ORCID: https://orcid.org/0000-0001-9386-9001)
- Haiyan Lei (ORCID: https://orcid.org/0000-0002-9955-6281)
- Christine M. Heske (ORCID: https://orcid.org/0000-0003-0956-6249)
- Morgan B. Carter
- Carleen Maitland
- Arnulfo Mendoza (ORCID: https://orcid.org/0009-0009-6082-9711)
- Carly M. Sayers (ORCID: https://orcid.org/0000-0001-8554-0281)
- Lu Chen (ORCID: https://orcid.org/0000-0001-9708-341X)
- Xiaohu Zhang (ORCID: https://orcid.org/0000-0002-0579-1636)
- Steven Shema (ORCID: https://orcid.org/0000-0002-7759-5407)
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
- National Center for Advancing Translational Sciences (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-07-26
- DOI
- https://doi.org/10.3390/cancers17152475
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00